North Staffordshire Joint Formulary
North Staffordshire Clinical Commissioning Group
Stoke-on-Trent Clinical Commissioning Group

 
back
8 Malignant disease and immunosuppression

For the most up to date list of agents funded by the Cancer Drugs Fund, please see Cancer Drug Fund List

The list should be read in conjunction with Appraisal and Funding of Cancer Drugs from July 2016 (including the new Cancer Drugs Fund).

08-01-01 Alkylating drugs

Bendamustine hydrochloride
Formulary

Restriction: In line with NICE Guidance only

MHRA/CHM advice: Bendamustine (Levact®): increased mortality observed in recent clinical studies in off-label use; monitor for opportunistic infections, hepatitis B reactivation (July 2017)

Link  NICE TA216: Bendamustine for the first-line treatment of chronic lymphocytic leukaemia
 

Cytotoxic Drug  Red View adult BNF  View SPC online  View childrens BNF  HCD  CDF
Carmustine Gliadel®
Formulary

Restriction: In line with NICE Guidance only

 

Link  NICE TA121: Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma
 

Cytotoxic Drug  Red View adult BNF  View SPC online  View childrens BNF  HCD